ArticleNeural regeneration research2026
The potential and therapeutic advances of the integrin family in neurological disorders.
Article in Neural regeneration research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Roles and therapeutic prospects of the laminin family in disorders of the nervous system.Journal of translational medicine · 2026Review
- The meningeal lymphatic vessel-peripheral immune axis: a novel therapeutic target in neurodegenerative diseases.Journal of neuroinflammation · 2026Review
- Identification and Verification of Anoikis-related Genes in Epilepsy Through Bioinformatics Analysis.Brain and behavior · 2026Article
- Migrasome as a novel organelle: Biogenesis, physiological functions, and therapeutic potential.Journal of translational internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurological disorders encompass a diverse and heterogeneous group of medical conditions, including cerebrovascular diseases (e.g., stroke), neurodegenerative diseases (e.g., Alzheimer's disease and Parkinson's disease), and autoimmune demyelinating disorders (e.g., multiple sclerosis). With the global aging population, the incidence of these disorders continues to rise, posing significant challenges to healthcare systems and socio-economic structures. Recent studies have highlighted integrins-a family of transmembrane glycoprotein receptors-as critical regulators of central nervous system function, making them a focal point in neurological disease research. By interacting with the extracellular matrix, integrins modulate cell adhesion, signal transduction, and inflammatory responses, playing indispensable roles in neuronal development, synaptic plasticity, and blood-brain barrier maintenance. Dysregulated integrin signaling has been implicated in the pathophysiology of various neurological disorders, suggesting that integrin-targeting interventions, including integrin antagonists or agonists, could represent novel therapeutic strategies. Preclinical and clinical studies have demonstrated that modulating integrin function influences disease progression, offering promising avenues for the development of precision medicine approaches. This review provides a comprehensive analysis of integrin structure, classification, and their physiological and pathological roles in the central nervous system, with a focus on their molecular mechanisms in neurological disorders. Furthermore, we evaluate the therapeutic potential and challenges associated with integrin-targeted interventions. By elucidating the mechanistic underpinnings of integrin function in the central nervous system, this review aims to advance our understanding of their translational potential, laying the groundwork for the development of innovative therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.